SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $2,056,733,459 |
| Positions | 33 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ZYMEWORKS INC | ZYME | COM | $600,445,942 | 22,970,388 |
| ANAPTYSBIO INC | ANAB | COM | $531,906,345 | 7,880,094 |
| AKTIS ONCOLOGY INC | AKTS | COM | $155,492,636 | 4,824,469 |
| CG ONCOLOGY INC | CGON | COM | $106,170,015 | 1,494,300 |
| ETON PHARMACEUTICALS INC | ETON | COM | $78,624,156 | 2,171,938 |
| CRISPR THERAPEUTICS AG | CRSP | NAMEN AKT | $75,771,113 | 1,389,276 |
| ORIC PHARMACEUTICALS INC | ORIC | COM | $72,865,496 | 6,728,116 |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | ORD SHS ADDED | $63,871,322 | 3,174,519 |
| LAKEFRONT BIOTHERAPEUTICS NV | LKFT | SPON ADR | $49,980,228 | 1,667,119 |
| NEUROGENE INC | NGNE | COM | $39,983,706 | 1,271,342 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.